Find
Contact | Legal Notice
Home > Research and Development > Scientific Publications

Scientific Publications

Year

1 2 3 4 5 6 7 8 9 10 Next

Treatment of Alzheimer’s Disease with the GSK-3 Inhibitor Tideglusib: A Pilot Study

Author/Authors: Teodoro del Ser, Klaus C. Steinwachs, Hermann J. Gertz, María V. Andrés, Belén Gómez-Carrillo, Miguel Medina, Joan A. Vericat, Pilar Redondo, David Fleet and Teresa León
Signature: Journal of Alzheimer’s Disease 33 (2013) 205–215
PDF Download (228 KB)  More Information

Evidence for the irreversible inhibition of Glycogen Synthase Kinase-3beta by tideglusib

Author/Authors: J.M. Domínguez, A. Fuertes, L. Orozco, M. del Monte-Millán, E. Delgado, M. Medina
Signature: Journal of Biological Chemistry, 2012, 287(2), 893-904

Recent Developments in Tau-based Therapeutics for Neurodegenerative Diseases

Author/Authors: M. Medina
Signature: Recent Patents on CNS Drug Discovery, 2011, 6(1), 20-30

Deconstructing GSK-3: The Fine Regulation of Its Activity

Author/Authors: M. Medina, F. Wandosell
Signature: International Journal of Alzheimer’s Disease, 2011, 2011, 479249

Modulation of GSK-3 as a therapeutic strategy on taupathologies

Author/Authors: M. Medina, J.J. Garrido, F. Wandosell
Signature: Frontiers in Molecular Neurosciences, 2011, 4(24), 1-10

Overcoming Cell Death and Tau Phosphorylation Mediated by PI3KInhibition: A Cell Assay to Measure Neuroprotection

Author/Authors: D. Simon, M. Medina, J. Avila and F. Wandosell
Signature: CNS & Neurological Disorders - Drug Targets, 2011, 10, 2, 208-214

Glycogen Synthase Kinase-3 (GSK-3) Inhibitors For The Treatment of Alzheimer’s Disease

Author/Authors: M. Medina, J. Ávila
Signature: Current Pharmaceutical Design, 2010, 16, 25, 2790-2798

Tau-knockout mice show reduced GSK3-induced hippocampal degeneration and learning deficits

Author/Authors: Elena Gómez de Barreda, Mar Pérez, Pilar Gómez Ramos, Javier de Cristobal, Patricia Martín-Maestro, Asunción Morán, Hana N. Dawson, Michael P. Vitek, José J. Lucas, Félix Hernández, Jesús Avila
Signature: Neurobiology of Disease, Volume 37. Issue 3, March 2010, Pages 622-629

Phase IIa Clinical Trial on Alzheimer's disease with NP12, a GSK-3 inhibitor

Author/Authors: T. del Ser
Signature: Alzheimer&Dementia 2010;6,Suppl 1;147

Neuronal in vitro models for the estimation of acute systemic toxicity

Author/Authors: A. Forsby, A.K. Bal-Price, A. Camins, S. Coecke, N. Fabre, H. Gustafsson, P. Honegger, A. Kinsner-Ovaskainen, M. Pallas, V. Rimbau, E. Rodríguez-Farré, C. Suñol, J.A. Vericat, M.G. Zurich

Signature: Toxicology in Vitro, 2009, 23, 1564-1569
1 2 3 4 5 6 7 8 9 10 Next

Interest Information

Postal Adress:
Noscira, S.A.
Avda. de la Industria, 52
Tres Cantos 28760 - Madrid (Spain)

E-mail adresses:
Administration and General services:
noscira@noscira.com
Research:
info_di@noscira.com

Phone Numbers:
Tel. +34 91 806 11 30
Fax. +34 91 803 46 60
   © 2008 Noscira, S.A.en Liquidación liquidacion@noscira.com